Topline Results of a Phase 2 Study of Subcutaneous IMVT-1401 in Patients with Generalized Myasthenia Gravis

被引：0
|
作者：
Benatar, Michael [1 ]
Breiner, Ari [2 ]
Bril, Vera [3 ]
Nowak, Richard [4 ]
Dunn, Imogene [5 ]
Jacobs, Alan [5 ]
机构：
[1] Univ Miami, Coral Gables, FL 33124 USA
[2] Ottawa Hosp, Civ Campus, Ottawa, ON, Canada
[3] Toronto Gen Hosp, Toronto, ON, Canada
[4] Yale Univ, Sch Med, New Haven, CT 06520 USA
[5] Immunovant Inc, New York, NY USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1417
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED PHASE-2 STUDY OF SUBCUTANEOUS BATOCLIMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
    Nowak, Richard
    Benatar, Michael
    Benatar, Michael
    Breiner, Ari
    Xu, Jing
    Bril, Vera
    MUSCLE & NERVE, 2022, 66 : S144 - S144
  • [2] SAFETY AND EFFICACY OF SUBCUTANEOUS IMMUNOGLOBULIN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
    Katzberg, Hans
    Idiaquez, Juan
    Mendoza, Meg
    Barnett, Carolina
    Huszti, Ella
    Lovblom, Erik
    Wang, Stella
    Bril, Vera
    MUSCLE & NERVE, 2024, 70 (03) : 683 - 683
  • [3] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: Phase 3 adapt study results
    Mantegazza, Renato
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Peric, Stojan
    Margania, Temur
    Murai, Hiroyuki
    Bilinska, Malgorzata
    Shakarishvili, Roman
    Smilowski, Marek
    Guglietta, Antonio
    Ulrichts, Peter
    Vangeneugden, Tony
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Howard, James
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2021, 429
  • [4] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: phase 3 adapt study results
    Mantegazza, R.
    Bril, V.
    Vu, T.
    Karam, C.
    Peric, S.
    Margania, T.
    Murai, H.
    Biliska, M.
    Shakarishvili, R.
    Smilowski, M.
    Guglietta, A.
    Ulrichts, P.
    Vangeneugden, T.
    Utsugisawa, K.
    Verschuuren, J.
    Howard, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 80 - 80
  • [5] A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF SUBCUTANEOUS BATOCLIMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS
    Nowak, Richard J.
    Benatar, Michael
    Breiner, Ari
    Isaacman, Daniel J.
    Bril, Vera
    MUSCLE & NERVE, 2022, 65 : S21 - S21
  • [6] Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extension
    Nowak, Richard J.
    Breiner, Ari
    Bril, Vera
    Allen, Jeffrey A.
    Khan, Shaida
    Levine, Todd
    Jacobs, Daniel H.
    Sahagian, Gregory
    Siddiqi, Zaeem A.
    Xu, Jing
    Macias, William L.
    Benatar, Michael
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (01): : 194 - 206
  • [7] SELF-ADMINISTRATION OF SUBCUTANEOUS ROZANOLIXIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: CLINICAL STUDY DESIGN
    Mehta, Rachana K. Gandhi
    Bril, Vera
    Antozzi, Carlo
    Berkowicz, Tomasz
    Druzdz, Artur
    Mahuwala, Zabeen K.
    Zschuentzsch, Jana
    Flemm, Denis
    Lavrov, Andreea
    Morris, Mark
    Singh, Puneet
    Snipes, Rose
    Leite, M. Isabel
    MUSCLE & NERVE, 2024, 70 (03) : 529 - 529
  • [8] EFFICACY AND SAFETY OF NIPOCALIMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: TOPLINE RESULTS FROM THE DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED PHASE 3 VIVACITY-MG3 STUDY
    Vu, Tuan
    Antozzi, Carlo
    Ramchandren, Sindhu
    Nowak, Richard J.
    Farmakidis, Constantine
    Bril, Vera
    De Bleecker, Jan
    Yang, Huan
    Minks, Eduard
    Park, Jin-Sung
    Grudniak, Mariusz
    Smilowski, Marek
    Sevilla, Teresa
    Hoffmann, Sarah
    Sivakumar, Kumaraswamy
    Youssef, Eriene
    Sanga, Panna
    Karcher, Keith
    Zhu, Yaowei
    Ling, Leona
    Sun, Hong
    MUSCLE & NERVE, 2024, 70 (03) : 655 - 655
  • [9] Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
    Howard, James F., Jr.
    Bril, Vera
    Burns, Ted M.
    Mantegazza, Renato
    Bilinska, Malgorzata
    Szczudlik, Andrzej
    Beydoun, Said
    De Rivera Garrido, Francisco Javier Rodriguez
    Piehl, Fredrik
    Rottoli, Mariarosa
    Van Damme, Philip
    Tuan Vu
    Evoli, Amelia
    Freimer, Miriam
    Mozaffar, Tahseen
    Ward, E. Sally
    Dreier, Torsten
    Ulrichts, Peter
    Verschueren, Katrien
    Guglietta, Antonio
    de Haard, Hans
    Leupin, Nicolas
    Verschuuren, Jan J. G. M.
    Claeys, Kristl
    Diez-Tejedor, Exuperio
    Mathew, Veena
    Sgarzi, Manlio
    Harvey, Brittany Leigh
    Farias, Jerrica
    Frangiomore, Rita
    Heintzman, Sarah
    de Meel, Robert
    Chopra, Manisha
    Alboini, Paolo Emilio
    Hietala, Albert
    Genge, Angela
    NEUROLOGY, 2019, 92 (23) : E2661 - E2673
  • [10] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 STUDY OF INEBILIZUMAB IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS (MINT): TOPLINE EFFICACY AND SAFETY FINDINGS
    Nowak, Richard
    Utsugisawa, Kimiaki
    Benatar, Michael
    Ciafaloni, Emma
    Leite, M. Isabel
    Vissing, John
    Tang, Fengming
    Wu, Yanping
    Rojavin, Mikhail
    Rampal, Nishi
    Howard, James, Jr.
    MUSCLE & NERVE, 2024, 70 (03) : 653 - 654
12345